Drugs / PB-119
PB-119
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05328843 | May → Oct 2022 | type 2 diabetes mellitus | PegBio Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03072407 | Nov 2015 → Nov 2016 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03059719 | Apr 2015 → Sep 2016 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03062774 | Nov 2014 → Sep 2016 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02084251 | Feb → Nov 2014 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06350812 | May → Nov 2024 | obesity disorder | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03604419 | Jun 2018 → Jul 2019 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03520972 | Jun 2018 → Jul 2019 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04504396 | Jun 2020 → Sep 2022 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB119 | “PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist.” NCT04504396 ↗10“PB119 injection 25ug or 50ug once each week, for three months” NCT03059719 ↗ “Pegylated Exenatide Injection (PB-119)” NCT05328843 ↗ |
| Known as | exenatide | “The current study investigated the safety and efficacy of once-weekly PB-119, a PEGylated exenatide injection, in treatment-naive patients with type 2 diabetes.” PMID 33687487 ↗ Mar 2021 |
| Known as | PEGylated exenatide | “PEGylated exenatide (study code: PB-119) needs to be administered only once a week.” PMID 33576936 ↗ Feb 2021 |
| Known as | Polyethylene glycolated exenatide | “Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.” PMID 32006325 ↗ Jun 2020 |
| Action | Activate | “receptor agonist” NCT04504396 ↗ |
| Modality | Peptide | “PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist.” NCT04504396 ↗ |
| Route | Subcutaneous | “twelve once-weekly subcutaneous doses of PB-119” NCT03059719 ↗ |